Crohn’s disease In the CD cohort of the RELIEVE UCCD study, 26% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD)* ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback